{"id":337454,"date":"2025-08-19T11:56:21","date_gmt":"2025-08-19T11:56:21","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-cassava-sciences\/"},"modified":"2025-08-19T11:56:21","modified_gmt":"2025-08-19T11:56:21","slug":"how-to-buy-cassava-sciences","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/","title":{"rendered":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-337454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Cassava Sciences, Inc. (SAVA) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve bu volatil biyoteknoloji hissesinde bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 vermek i\u00e7in kapsaml\u0131 analizimizi inceleyin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Cassava Sciences, Inc. (SAVA) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve bu volatil biyoteknoloji hissesinde bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 vermek i\u00e7in kapsaml\u0131 analizimizi inceleyin."},"intro":"Biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n y\u00fcksek riskli d\u00fcnyas\u0131na dalmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Cassava Sciences (SAVA), \u015fu anda ila\u00e7 sekt\u00f6r\u00fcndeki en ilgin\u00e7 ve volatil f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famadaki bu \u015firket, 2025 boyunca dramatik stratejik de\u011fi\u015fiklikler ve yat\u0131r\u0131mc\u0131 portf\u00f6ylerini ya g\u00fc\u00e7lendirebilecek ya da zay\u0131flatabilecek klinik deneme geli\u015fmeleriyle man\u015fetlerde yer ald\u0131. Size mevcut hisse performans\u0131ndan Cassava Sciences, Inc. (SAVA) hissesine yat\u0131r\u0131m i\u00e7in pratik ad\u0131mlara kadar her \u015feyi anlataca\u011f\u0131z ve bu karma\u015f\u0131k ama potansiyel olarak \u00f6d\u00fcllendirici f\u0131rsatta yol g\u00f6sterece\u011fiz.","intro_source":{"label":"Intro","type":"text","formatted_value":"Biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n y\u00fcksek riskli d\u00fcnyas\u0131na dalmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Cassava Sciences (SAVA), \u015fu anda ila\u00e7 sekt\u00f6r\u00fcndeki en ilgin\u00e7 ve volatil f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famadaki bu \u015firket, 2025 boyunca dramatik stratejik de\u011fi\u015fiklikler ve yat\u0131r\u0131mc\u0131 portf\u00f6ylerini ya g\u00fc\u00e7lendirebilecek ya da zay\u0131flatabilecek klinik deneme geli\u015fmeleriyle man\u015fetlerde yer ald\u0131. Size mevcut hisse performans\u0131ndan Cassava Sciences, Inc. (SAVA) hissesine yat\u0131r\u0131m i\u00e7in pratik ad\u0131mlara kadar her \u015feyi anlataca\u011f\u0131z ve bu karma\u015f\u0131k ama potansiyel olarak \u00f6d\u00fcllendirici f\u0131rsatta yol g\u00f6sterece\u011fiz."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2> <p>19 A\u011fustos 2025 itibar\u0131yla Cassava Sciences (SAVA) hisseleri <strong>2,27 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin Alzheimer hastal\u0131\u011f\u0131 ara\u015ft\u0131rmalar\u0131ndan T\u00fcber\u00f6z Skleroz Kompleksi (TSC) ile ili\u015fkili epilepsi tedavilerine stratejik y\u00f6neliminin ard\u0131ndan kritik bir d\u00f6n\u00fcm noktas\u0131n\u0131 temsil ediyor.<\/p> <p>Hisse senedi, son bir y\u0131l i\u00e7inde a\u015f\u0131r\u0131 volatilite ya\u015fad\u0131; 52 haftal\u0131k aral\u0131kta en y\u00fcksek <strong>33,98 $<\/strong> ve en d\u00fc\u015f\u00fck <strong>1,15 $<\/strong> seviyelerinde i\u015flem g\u00f6rd\u00fc. Yakla\u015f\u0131k <strong>113 milyon $<\/strong> piyasa de\u011feri ile SAVA, mikro sermayeli bir hisse senedi olarak s\u0131n\u0131fland\u0131r\u0131l\u0131r; bu da genellikle daha y\u00fcksek risk ama ayn\u0131 zamanda bilgili yat\u0131r\u0131mc\u0131lar i\u00e7in daha y\u00fcksek potansiyel getiri anlam\u0131na gelir.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\uddd3\ufe0f Fiyat Hareketleri \u0130\u00e7in Kritik Tarihler<\/h2> <p>Kas\u0131m 2025 tarihini takviminize i\u015faretleyin; Cassava Sciences'in bir sonraki kazan\u00e7 raporunu yay\u0131nlamas\u0131 bekleniyor. Tarihsel olarak, biyoteknoloji kazan\u00e7 duyurular\u0131 SAVA hisselerinde dramatik fiyat dalgalanmalar\u0131na neden olmu\u015ftur.<\/p> <p><strong>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/strong><\/p> <ul> <li><strong>14 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 sonras\u0131 %2,9 d\u00fc\u015f\u00fc\u015fle 2,34 $<\/li> <li><strong>\u00d6nceki \u00e7eyrek<\/strong>: Kazan\u00e7 sonras\u0131 30 g\u00fcn i\u00e7inde ortalama %7,29 toparlanma ile kar\u0131\u015f\u0131k tepkiler<\/li> <li><strong>Tarihsel desen<\/strong>: Kazan\u00e7 ka\u00e7\u0131rmalar\u0131 genellikle k\u0131sa vadeli d\u00fc\u015f\u00fc\u015flere ve ard\u0131ndan potansiyel toparlanmaya yol a\u00e7ar<\/li> <\/ul> <p>Kas\u0131m raporu, \u015firketin yeni TSC odakl\u0131 stratejisi ve Haziran 2025 itibar\u0131yla 112,4 milyon $ olan nakit t\u00fcketim oran\u0131 hakk\u0131nda g\u00fcncellemeler sa\u011flayaca\u011f\u0131 i\u00e7in \u00f6zellikle kritik olacak.<\/p>  <h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Fiyat Seyri ve Trend Analizi<\/h2> <p>Cassava Sciences, son alt\u0131 ayda yat\u0131r\u0131mc\u0131lar\u0131 adeta bir h\u0131z treni yolculu\u011funa \u00e7\u0131kard\u0131:<\/p> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ay<\/th> <th>Fiyat Aral\u0131\u011f\u0131<\/th> <th>\u00d6nemli Olaylar<\/th> <\/tr> <\/thead> <tbody> <tr> <td><strong>\u015eubat 2025<\/strong><\/td> <td>3,50 $-4,20 $<\/td> <td>Alzheimer \u00f6ncesi deneme hayal k\u0131r\u0131kl\u0131\u011f\u0131<\/td> <\/tr> <tr> <td><strong>Mart 2025<\/strong><\/td> <td>2,80 $-3,50 $<\/td> <td>\u0130lk olumsuz deneme sonu\u00e7lar\u0131 ortaya \u00e7\u0131k\u0131yor<\/td> <\/tr> <tr> <td><strong>Nisan 2025<\/strong><\/td> <td>1,80 $-2,50 $<\/td> <td>Deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 sonras\u0131 %40 hisse d\u00fc\u015f\u00fc\u015f\u00fc<\/td> <\/tr> <tr> <td><strong>May\u0131s 2025<\/strong><\/td> <td>2,00 $-2,80 $<\/td> <td>Stratejik g\u00f6zden ge\u00e7irme d\u00f6nemi<\/td> <\/tr> <tr> <td><strong>Haziran 2025<\/strong><\/td> <td>2,20 $-2,60 $<\/td> <td>TSC program\u0131 duyurusu<\/td> <\/tr> <tr> <td><strong>Temmuz 2025<\/strong><\/td> <td>2,30 $-2,70 $<\/td> <td>Olumlu preklinik veri a\u00e7\u0131klamas\u0131<\/td> <\/tr> <tr> <td><strong>A\u011fustos 2025<\/strong><\/td> <td>2,20 $-2,40 $<\/td> <td>2. \u00e7eyrek kazan\u00e7lar\u0131 ve yasal uzla\u015fma etkisi<\/td> <\/tr> <\/tbody> <\/table> <p>Alzheimer program\u0131n\u0131n sonland\u0131r\u0131lmas\u0131na ra\u011fmen hisse senedi son \u00fc\u00e7 ayda %<strong>49,7<\/strong> art\u0131\u015f g\u00f6sterdi; bu, genel piyasan\u0131n %16,0 getirisinin olduk\u00e7a \u00fczerinde. Bu \u00fcst\u00fcn performans, yat\u0131r\u0131mc\u0131lar\u0131n yeni TSC odakl\u0131 y\u00f6nelimde potansiyel g\u00f6rd\u00fc\u011f\u00fcn\u00fc g\u00f6steriyor.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve \u015firketin stratejik yeniden konumland\u0131rmas\u0131na dayanarak:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu Tahmini<\/strong>: 2,40 $-3,40 $ aral\u0131\u011f\u0131 (%90 olas\u0131l\u0131k) <ul> <li><strong>Karar<\/strong>: BEKLE - Daha net TSC deneme verileri beklenmeli<\/li> <\/ul> <\/li> <li><strong>2026 Projeksiyonu<\/strong>: 2,80 $-3,50 $ <ul> <li>\u0130lk insan TSC deneme sonu\u00e7lar\u0131 bekleniyor<\/li> <li>Olas\u0131 ortakl\u0131k duyurular\u0131<\/li> <\/ul> <\/li> <li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 4,00 $-8,00 $ <ul> <li>Faz 2 TSC denemesinin tamamlanmas\u0131 m\u00fcmk\u00fcn<\/li> <li>Reg\u00fclasyon s\u00fcreci daha net<\/li> <\/ul> <\/li> <li><strong>2030 Uzun Vadeli<\/strong>: 0,70 $-15,00 $ (a\u015f\u0131r\u0131 de\u011fi\u015fkenlik) <ul> <li>Ya ba\u015far\u0131l\u0131 ticarile\u015fme ya da devam eden zorluklar<\/li> <\/ul> <\/li> <\/ul> <p>Geni\u015f aral\u0131k, biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n ikili do\u011fas\u0131n\u0131 yans\u0131t\u0131yor - ya TSC program\u0131 dramatik \u015fekilde ba\u015far\u0131l\u0131 olur ya da \u015firket zorluklarla kar\u015f\u0131la\u015fmaya devam eder.<\/p>  <h2>\u26a0\ufe0f SAVA Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Risk Analizi<\/h2> <h3>Y\u00fcksek Risk Fakt\u00f6rleri<\/h3> <ul> <li><strong>Klinik Deneme Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: T\u00fcm de\u011ferleme TSC epilepsi program\u0131n\u0131n ba\u015far\u0131s\u0131na ba\u011fl\u0131<\/li> <li><strong>Nakit T\u00fcketim Endi\u015feleri<\/strong>: 112,4 milyon $ nakit pozisyonu ve y\u00fcksek operasyonel zararlar<\/li> <li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onay s\u00fcre\u00e7leri \u00f6ng\u00f6r\u00fclemez<\/li> <li><strong>Rekabet<\/strong>: Benzer nadir hastal\u0131k pazarlar\u0131n\u0131 hedefleyen di\u011fer \u015firketler<\/li> <li><strong>Hisse Volatilitesi<\/strong>: 52 haftal\u0131k aral\u0131k 1,15 $ ile 33,98 $ aras\u0131nda a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131 g\u00f6steriyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Olumlu \u0130\u015faretler<\/h3> <ul> <li><strong>Stratejik Y\u00f6n De\u011fi\u015fikli\u011fi Tamamland\u0131<\/strong>: Ba\u015far\u0131s\u0131z Alzheimer program\u0131ndan tamamen kopu\u015f<\/li> <li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 112,4 milyon $ 2026 y\u0131l\u0131na kadar finansal destek sa\u011fl\u0131yor<\/li> <li><strong>Preklinik Umut Verici Sonu\u00e7lar<\/strong>: TSC epilepsi i\u00e7in te\u015fvik edici hayvan \u00e7al\u0131\u015fmas\u0131 sonu\u00e7lar\u0131<\/li> <li><strong>Piyasa \u0130htiyac\u0131<\/strong>: TSC ile ili\u015fkili epilepsi kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 temsil ediyor<\/li> <li><strong>Deneyimli Liderlik<\/strong>: Yeni klinik geli\u015ftirme atamalar\u0131<\/li> <\/ul>  <h2>\ud83d\udcf0 \u00d6nemli Haberlerin Etki Analizi<\/h2> <p>Son alt\u0131 ay Cassava Sciences i\u00e7in d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc oldu:<\/p> <ul> <li><strong>Nisan 2025<\/strong>: Alzheimer program\u0131n\u0131n sonland\u0131r\u0131lmas\u0131 %40 hisse d\u00fc\u015f\u00fc\u015f\u00fcne neden oldu <ul> <li><strong>T\u00fcccar dersi<\/strong>: B\u00fcy\u00fck klinik ba\u015far\u0131s\u0131zl\u0131klar cesur yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m f\u0131rsatlar\u0131 yarat\u0131r<\/li> <\/ul> <\/li> <li><strong>Haziran 2025<\/strong>: TSC program\u0131 duyurusu %20 toparlanma sa\u011flad\u0131 <ul> <li><strong>Desen<\/strong>: Biyoteknoloji y\u00f6n de\u011fi\u015fiklikleri, yeni y\u00f6n bilimsel merit ta\u015f\u0131yorsa genellikle \u00f6d\u00fcllendirilir<\/li> <\/ul> <\/li> <li><strong>A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 44,2 milyon $ zarar g\u00f6sterdi ancak g\u00fc\u00e7l\u00fc nakit pozisyonu vard\u0131 <ul> <li><strong>\u0130\u00e7g\u00f6r\u00fc<\/strong>: Geli\u015fim a\u015famas\u0131ndaki biyoteknolojiler i\u00e7in nakit runway, \u00e7eyreklik zararlar\u0131ndan daha \u00f6nemlidir<\/li> <\/ul> <\/li> <\/ul> <p>Her haber olay\u0131, duyurulardan sonraki haftalarda ortalama %15-25 fiyat dalgalanmalar\u0131 ile ticaret f\u0131rsatlar\u0131 yaratt\u0131.<\/p>  <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2'sinden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Toplu yat\u0131r\u0131m yerine k\u00fc\u00e7\u00fck ayl\u0131k al\u0131mlar yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: 1,50 $ destek seviyesinin alt\u0131ndaki a\u015f\u0131r\u0131 d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li> <li><strong>Klinik G\u00fcncellemeleri Takip Edin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve 2026 TSC denemeleri kritik \u00f6nemde<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"SAVA ticareti, biyoteknolojide fl\u00f6rt etmek gibidir - Faz 3 sonu\u00e7lar\u0131 gelene kadar heyecan vericidir!\"<\/li> <\/ol>  <h2>\u2705 Ad\u0131m Ad\u0131m: Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ eri\u015fimi ve d\u00fc\u015f\u00fck komisyon \u00fccretleri sundu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Hissenin volatilitesi g\u00f6z \u00f6n\u00fcne al\u0131narak k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>G\u00fcncel Fiyat\u0131 Ara\u015ft\u0131r\u0131n<\/td> <td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 2,27 $ (19 A\u011fustos 2025) olarak kontrol edin<\/td> <\/tr> <tr> <td>4<\/td> <td>Limit Emirleri Kullan\u0131n<\/td> <td>Fiyat s\u0131\u00e7ramalar\u0131nda fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131 belirleyin<\/td> <\/tr> <tr> <td>5<\/td> <td>Sipari\u015f Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td> <td>Hisse adedi ve toplam maliyeti onaylay\u0131n<\/td> <\/tr> <tr> <td>6<\/td> <td>Pozisyonu Takip Edin<\/td> <td>\u00d6nemli destek\/diren\u00e7 seviyeleri i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td> <\/tr> <tr> <td>7<\/td> <td>\u00c7\u0131k\u0131\u015f Stratejisi Planlay\u0131n<\/td> <td>K\u00e2r alma ve stop-loss seviyelerini \u00f6nceden belirleyin<\/td> <\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Cassava Sciences, Inc. (SAVA) hissesine yat\u0131r\u0131m yapmay\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option, biyoteknoloji stratejilerini test etmek i\u00e7in m\u00fckemmel birka\u00e7 avantaj sunar:<\/p> <p><strong>Sadece 5 $ minimum depozito<\/strong>, SAVA gibi volatil hisselerde k\u00fc\u00e7\u00fck pozisyonlarla deneme yapman\u0131z\u0131 sa\u011flar ve b\u00fcy\u00fck risk olu\u015fturmaz. Platformun <strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>, tek bir belge ile hemen i\u015flem yapmaya ba\u015flaman\u0131za olanak tan\u0131r. <strong>100'den fazla para \u00e7ekme y\u00f6ntemi<\/strong> (kripto ve e-c\u00fczdanlar dahil) sayesinde, SAVA i\u015fleminiz ba\u015far\u0131l\u0131 olursa kazan\u00e7lar\u0131n\u0131za h\u0131zl\u0131ca eri\u015febilirsiniz.<\/p>  <h2>\ud83c\udfe2 Cassava Sciences \u015eirket Profili 2025<\/h2> <p>Cassava Sciences, Austin, Teksas merkezli klinik a\u015famada bir biyoteknoloji \u015firketidir ve 2025 y\u0131l\u0131nda dramatik bir d\u00f6n\u00fc\u015f\u00fcm ge\u00e7irmi\u015ftir. Ba\u015flang\u0131\u00e7ta simufilam adl\u0131 Alzheimer hastal\u0131\u011f\u0131 ila\u00e7 aday\u0131na odaklanan \u015firket, ge\u00e7 a\u015fama deneme sonu\u00e7lar\u0131n\u0131n hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratmas\u0131n\u0131n ard\u0131ndan tamamen T\u00fcber\u00f6z Skleroz Kompleksi ile ili\u015fkili epilepsiye y\u00f6nelmi\u015ftir.<\/p> <p>\u015eirket, yakla\u015f\u0131k 30 \u00e7al\u0131\u015fanla k\u00fc\u00e7\u00fck ve verimli bir operasyon s\u00fcrd\u00fcrmekte olup, Haziran 2025 itibar\u0131yla 112,4 milyon $ sa\u011flam bir nakit pozisyonuna sahiptir. Tam stratejik de\u011fi\u015fimi, kalabal\u0131k Alzheimer alan\u0131n\u0131 terk edip \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f ihtiyac\u0131 olan ni\u015f bir nadir hastal\u0131k pazar\u0131na y\u00f6nelmesiyle hem b\u00fcy\u00fck risk hem de potansiyel \u00f6d\u00fcl anlam\u0131na gelir.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Cassava Sciences'in ara\u015ft\u0131rma y\u00f6nelimi o kadar dramatikti ki, 6 milyon Amerikal\u0131y\u0131 etkileyen bir hastal\u0131ktan (Alzheimer) d\u00fcnya \u00e7ap\u0131nda sadece 50.000 ki\u015fiyi etkileyen bir hastal\u0131\u011fa (TSC ile ili\u015fkili epilepsi) y\u00f6neldi - potansiyel hasta pop\u00fclasyonunda %99,2 azalma, ancak hasta ba\u015f\u0131na \u00e7ok daha y\u00fcksek tedavi de\u011feri potansiyeli.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2>\n<p>19 A\u011fustos 2025 itibar\u0131yla Cassava Sciences (SAVA) hisseleri <strong>2,27 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin Alzheimer hastal\u0131\u011f\u0131 ara\u015ft\u0131rmalar\u0131ndan T\u00fcber\u00f6z Skleroz Kompleksi (TSC) ile ili\u015fkili epilepsi tedavilerine stratejik y\u00f6neliminin ard\u0131ndan kritik bir d\u00f6n\u00fcm noktas\u0131n\u0131 temsil ediyor.<\/p>\n<p>Hisse senedi, son bir y\u0131l i\u00e7inde a\u015f\u0131r\u0131 volatilite ya\u015fad\u0131; 52 haftal\u0131k aral\u0131kta en y\u00fcksek <strong>33,98 $<\/strong> ve en d\u00fc\u015f\u00fck <strong>1,15 $<\/strong> seviyelerinde i\u015flem g\u00f6rd\u00fc. Yakla\u015f\u0131k <strong>113 milyon $<\/strong> piyasa de\u011feri ile SAVA, mikro sermayeli bir hisse senedi olarak s\u0131n\u0131fland\u0131r\u0131l\u0131r; bu da genellikle daha y\u00fcksek risk ama ayn\u0131 zamanda bilgili yat\u0131r\u0131mc\u0131lar i\u00e7in daha y\u00fcksek potansiyel getiri anlam\u0131na gelir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\uddd3\ufe0f Fiyat Hareketleri \u0130\u00e7in Kritik Tarihler<\/h2>\n<p>Kas\u0131m 2025 tarihini takviminize i\u015faretleyin; Cassava Sciences&#8217;in bir sonraki kazan\u00e7 raporunu yay\u0131nlamas\u0131 bekleniyor. Tarihsel olarak, biyoteknoloji kazan\u00e7 duyurular\u0131 SAVA hisselerinde dramatik fiyat dalgalanmalar\u0131na neden olmu\u015ftur.<\/p>\n<p><strong>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/strong><\/p>\n<ul>\n<li><strong>14 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 sonras\u0131 %2,9 d\u00fc\u015f\u00fc\u015fle 2,34 $<\/li>\n<li><strong>\u00d6nceki \u00e7eyrek<\/strong>: Kazan\u00e7 sonras\u0131 30 g\u00fcn i\u00e7inde ortalama %7,29 toparlanma ile kar\u0131\u015f\u0131k tepkiler<\/li>\n<li><strong>Tarihsel desen<\/strong>: Kazan\u00e7 ka\u00e7\u0131rmalar\u0131 genellikle k\u0131sa vadeli d\u00fc\u015f\u00fc\u015flere ve ard\u0131ndan potansiyel toparlanmaya yol a\u00e7ar<\/li>\n<\/ul>\n<p>Kas\u0131m raporu, \u015firketin yeni TSC odakl\u0131 stratejisi ve Haziran 2025 itibar\u0131yla 112,4 milyon $ olan nakit t\u00fcketim oran\u0131 hakk\u0131nda g\u00fcncellemeler sa\u011flayaca\u011f\u0131 i\u00e7in \u00f6zellikle kritik olacak.<\/p>\n<h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Fiyat Seyri ve Trend Analizi<\/h2>\n<p>Cassava Sciences, son alt\u0131 ayda yat\u0131r\u0131mc\u0131lar\u0131 adeta bir h\u0131z treni yolculu\u011funa \u00e7\u0131kard\u0131:<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>\u00d6nemli Olaylar<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>\u015eubat 2025<\/strong><\/td>\n<td>3,50 $-4,20 $<\/td>\n<td>Alzheimer \u00f6ncesi deneme hayal k\u0131r\u0131kl\u0131\u011f\u0131<\/td>\n<\/tr>\n<tr>\n<td><strong>Mart 2025<\/strong><\/td>\n<td>2,80 $-3,50 $<\/td>\n<td>\u0130lk olumsuz deneme sonu\u00e7lar\u0131 ortaya \u00e7\u0131k\u0131yor<\/td>\n<\/tr>\n<tr>\n<td><strong>Nisan 2025<\/strong><\/td>\n<td>1,80 $-2,50 $<\/td>\n<td>Deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 sonras\u0131 %40 hisse d\u00fc\u015f\u00fc\u015f\u00fc<\/td>\n<\/tr>\n<tr>\n<td><strong>May\u0131s 2025<\/strong><\/td>\n<td>2,00 $-2,80 $<\/td>\n<td>Stratejik g\u00f6zden ge\u00e7irme d\u00f6nemi<\/td>\n<\/tr>\n<tr>\n<td><strong>Haziran 2025<\/strong><\/td>\n<td>2,20 $-2,60 $<\/td>\n<td>TSC program\u0131 duyurusu<\/td>\n<\/tr>\n<tr>\n<td><strong>Temmuz 2025<\/strong><\/td>\n<td>2,30 $-2,70 $<\/td>\n<td>Olumlu preklinik veri a\u00e7\u0131klamas\u0131<\/td>\n<\/tr>\n<tr>\n<td><strong>A\u011fustos 2025<\/strong><\/td>\n<td>2,20 $-2,40 $<\/td>\n<td>2. \u00e7eyrek kazan\u00e7lar\u0131 ve yasal uzla\u015fma etkisi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Alzheimer program\u0131n\u0131n sonland\u0131r\u0131lmas\u0131na ra\u011fmen hisse senedi son \u00fc\u00e7 ayda %<strong>49,7<\/strong> art\u0131\u015f g\u00f6sterdi; bu, genel piyasan\u0131n %16,0 getirisinin olduk\u00e7a \u00fczerinde. Bu \u00fcst\u00fcn performans, yat\u0131r\u0131mc\u0131lar\u0131n yeni TSC odakl\u0131 y\u00f6nelimde potansiyel g\u00f6rd\u00fc\u011f\u00fcn\u00fc g\u00f6steriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve \u015firketin stratejik yeniden konumland\u0131rmas\u0131na dayanarak:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu Tahmini<\/strong>: 2,40 $-3,40 $ aral\u0131\u011f\u0131 (%90 olas\u0131l\u0131k)\n<ul>\n<li><strong>Karar<\/strong>: BEKLE &#8211; Daha net TSC deneme verileri beklenmeli<\/li>\n<\/ul>\n<\/li>\n<li><strong>2026 Projeksiyonu<\/strong>: 2,80 $-3,50 $\n<ul>\n<li>\u0130lk insan TSC deneme sonu\u00e7lar\u0131 bekleniyor<\/li>\n<li>Olas\u0131 ortakl\u0131k duyurular\u0131<\/li>\n<\/ul>\n<\/li>\n<li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 4,00 $-8,00 $\n<ul>\n<li>Faz 2 TSC denemesinin tamamlanmas\u0131 m\u00fcmk\u00fcn<\/li>\n<li>Reg\u00fclasyon s\u00fcreci daha net<\/li>\n<\/ul>\n<\/li>\n<li><strong>2030 Uzun Vadeli<\/strong>: 0,70 $-15,00 $ (a\u015f\u0131r\u0131 de\u011fi\u015fkenlik)\n<ul>\n<li>Ya ba\u015far\u0131l\u0131 ticarile\u015fme ya da devam eden zorluklar<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Geni\u015f aral\u0131k, biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n ikili do\u011fas\u0131n\u0131 yans\u0131t\u0131yor &#8211; ya TSC program\u0131 dramatik \u015fekilde ba\u015far\u0131l\u0131 olur ya da \u015firket zorluklarla kar\u015f\u0131la\u015fmaya devam eder.<\/p>\n<h2>\u26a0\ufe0f SAVA Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Risk Analizi<\/h2>\n<h3>Y\u00fcksek Risk Fakt\u00f6rleri<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: T\u00fcm de\u011ferleme TSC epilepsi program\u0131n\u0131n ba\u015far\u0131s\u0131na ba\u011fl\u0131<\/li>\n<li><strong>Nakit T\u00fcketim Endi\u015feleri<\/strong>: 112,4 milyon $ nakit pozisyonu ve y\u00fcksek operasyonel zararlar<\/li>\n<li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onay s\u00fcre\u00e7leri \u00f6ng\u00f6r\u00fclemez<\/li>\n<li><strong>Rekabet<\/strong>: Benzer nadir hastal\u0131k pazarlar\u0131n\u0131 hedefleyen di\u011fer \u015firketler<\/li>\n<li><strong>Hisse Volatilitesi<\/strong>: 52 haftal\u0131k aral\u0131k 1,15 $ ile 33,98 $ aras\u0131nda a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131 g\u00f6steriyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Olumlu \u0130\u015faretler<\/h3>\n<ul>\n<li><strong>Stratejik Y\u00f6n De\u011fi\u015fikli\u011fi Tamamland\u0131<\/strong>: Ba\u015far\u0131s\u0131z Alzheimer program\u0131ndan tamamen kopu\u015f<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 112,4 milyon $ 2026 y\u0131l\u0131na kadar finansal destek sa\u011fl\u0131yor<\/li>\n<li><strong>Preklinik Umut Verici Sonu\u00e7lar<\/strong>: TSC epilepsi i\u00e7in te\u015fvik edici hayvan \u00e7al\u0131\u015fmas\u0131 sonu\u00e7lar\u0131<\/li>\n<li><strong>Piyasa \u0130htiyac\u0131<\/strong>: TSC ile ili\u015fkili epilepsi kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 temsil ediyor<\/li>\n<li><strong>Deneyimli Liderlik<\/strong>: Yeni klinik geli\u015ftirme atamalar\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udcf0 \u00d6nemli Haberlerin Etki Analizi<\/h2>\n<p>Son alt\u0131 ay Cassava Sciences i\u00e7in d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc oldu:<\/p>\n<ul>\n<li><strong>Nisan 2025<\/strong>: Alzheimer program\u0131n\u0131n sonland\u0131r\u0131lmas\u0131 %40 hisse d\u00fc\u015f\u00fc\u015f\u00fcne neden oldu\n<ul>\n<li><strong>T\u00fcccar dersi<\/strong>: B\u00fcy\u00fck klinik ba\u015far\u0131s\u0131zl\u0131klar cesur yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m f\u0131rsatlar\u0131 yarat\u0131r<\/li>\n<\/ul>\n<\/li>\n<li><strong>Haziran 2025<\/strong>: TSC program\u0131 duyurusu %20 toparlanma sa\u011flad\u0131\n<ul>\n<li><strong>Desen<\/strong>: Biyoteknoloji y\u00f6n de\u011fi\u015fiklikleri, yeni y\u00f6n bilimsel merit ta\u015f\u0131yorsa genellikle \u00f6d\u00fcllendirilir<\/li>\n<\/ul>\n<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 44,2 milyon $ zarar g\u00f6sterdi ancak g\u00fc\u00e7l\u00fc nakit pozisyonu vard\u0131\n<ul>\n<li><strong>\u0130\u00e7g\u00f6r\u00fc<\/strong>: Geli\u015fim a\u015famas\u0131ndaki biyoteknolojiler i\u00e7in nakit runway, \u00e7eyreklik zararlar\u0131ndan daha \u00f6nemlidir<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Her haber olay\u0131, duyurulardan sonraki haftalarda ortalama %15-25 fiyat dalgalanmalar\u0131 ile ticaret f\u0131rsatlar\u0131 yaratt\u0131.<\/p>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2&#8217;sinden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Toplu yat\u0131r\u0131m yerine k\u00fc\u00e7\u00fck ayl\u0131k al\u0131mlar yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: 1,50 $ destek seviyesinin alt\u0131ndaki a\u015f\u0131r\u0131 d\u00fc\u015f\u00fc\u015flere kar\u015f\u0131 koruma sa\u011flay\u0131n<\/li>\n<li><strong>Klinik G\u00fcncellemeleri Takip Edin<\/strong>: Kas\u0131m kazan\u00e7lar\u0131 ve 2026 TSC denemeleri kritik \u00f6nemde<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;SAVA ticareti, biyoteknolojide fl\u00f6rt etmek gibidir &#8211; Faz 3 sonu\u00e7lar\u0131 gelene kadar heyecan vericidir!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Ad\u0131m Ad\u0131m: Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve d\u00fc\u015f\u00fck komisyon \u00fccretleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Hissenin volatilitesi g\u00f6z \u00f6n\u00fcne al\u0131narak k\u00fc\u00e7\u00fck miktarlarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>G\u00fcncel Fiyat\u0131 Ara\u015ft\u0131r\u0131n<\/td>\n<td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 2,27 $ (19 A\u011fustos 2025) olarak kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit Emirleri Kullan\u0131n<\/td>\n<td>Fiyat s\u0131\u00e7ramalar\u0131nda fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td>\n<td>Hisse adedi ve toplam maliyeti onaylay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonu Takip Edin<\/td>\n<td>\u00d6nemli destek\/diren\u00e7 seviyeleri i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejisi Planlay\u0131n<\/td>\n<td>K\u00e2r alma ve stop-loss seviyelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Cassava Sciences, Inc. (SAVA) hissesine yat\u0131r\u0131m yapmay\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option, biyoteknoloji stratejilerini test etmek i\u00e7in m\u00fckemmel birka\u00e7 avantaj sunar:<\/p>\n<p><strong>Sadece 5 $ minimum depozito<\/strong>, SAVA gibi volatil hisselerde k\u00fc\u00e7\u00fck pozisyonlarla deneme yapman\u0131z\u0131 sa\u011flar ve b\u00fcy\u00fck risk olu\u015fturmaz. Platformun <strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong>, tek bir belge ile hemen i\u015flem yapmaya ba\u015flaman\u0131za olanak tan\u0131r. <strong>100&#8217;den fazla para \u00e7ekme y\u00f6ntemi<\/strong> (kripto ve e-c\u00fczdanlar dahil) sayesinde, SAVA i\u015fleminiz ba\u015far\u0131l\u0131 olursa kazan\u00e7lar\u0131n\u0131za h\u0131zl\u0131ca eri\u015febilirsiniz.<\/p>\n<h2>\ud83c\udfe2 Cassava Sciences \u015eirket Profili 2025<\/h2>\n<p>Cassava Sciences, Austin, Teksas merkezli klinik a\u015famada bir biyoteknoloji \u015firketidir ve 2025 y\u0131l\u0131nda dramatik bir d\u00f6n\u00fc\u015f\u00fcm ge\u00e7irmi\u015ftir. Ba\u015flang\u0131\u00e7ta simufilam adl\u0131 Alzheimer hastal\u0131\u011f\u0131 ila\u00e7 aday\u0131na odaklanan \u015firket, ge\u00e7 a\u015fama deneme sonu\u00e7lar\u0131n\u0131n hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratmas\u0131n\u0131n ard\u0131ndan tamamen T\u00fcber\u00f6z Skleroz Kompleksi ile ili\u015fkili epilepsiye y\u00f6nelmi\u015ftir.<\/p>\n<p>\u015eirket, yakla\u015f\u0131k 30 \u00e7al\u0131\u015fanla k\u00fc\u00e7\u00fck ve verimli bir operasyon s\u00fcrd\u00fcrmekte olup, Haziran 2025 itibar\u0131yla 112,4 milyon $ sa\u011flam bir nakit pozisyonuna sahiptir. Tam stratejik de\u011fi\u015fimi, kalabal\u0131k Alzheimer alan\u0131n\u0131 terk edip \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f ihtiyac\u0131 olan ni\u015f bir nadir hastal\u0131k pazar\u0131na y\u00f6nelmesiyle hem b\u00fcy\u00fck risk hem de potansiyel \u00f6d\u00fcl anlam\u0131na gelir.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Cassava Sciences&#8217;in ara\u015ft\u0131rma y\u00f6nelimi o kadar dramatikti ki, 6 milyon Amerikal\u0131y\u0131 etkileyen bir hastal\u0131ktan (Alzheimer) d\u00fcnya \u00e7ap\u0131nda sadece 50.000 ki\u015fiyi etkileyen bir hastal\u0131\u011fa (TSC ile ili\u015fkili epilepsi) y\u00f6neldi &#8211; potansiyel hasta pop\u00fclasyonunda %99,2 azalma, ancak hasta ba\u015f\u0131na \u00e7ok daha y\u00fcksek tedavi de\u011feri potansiyeli.<\/p>\n"},"faq":[{"question":"Cassava Sciences (SAVA) hisseleri nereden al\u0131nabilir?","answer":"SAVA hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"SAVA hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Y\u00fcksek volatilite, klinik deneme sonu\u00e7lar\u0131 ve \u015firketin nakit pozisyonu gibi fakt\u00f6rler yat\u0131r\u0131m kararlar\u0131n\u0131zda \u00f6nemli rol oynar. Riskleri anlamak ve k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak \u00f6nemlidir."},{"question":"Cassava Sciences'in stratejik de\u011fi\u015fikli\u011fi nedir?","answer":"\u015eirket, Alzheimer hastal\u0131\u011f\u0131 ara\u015ft\u0131rmalar\u0131ndan vazge\u00e7ip TSC ile ili\u015fkili epilepsi tedavilerine odaklanmak \u00fczere stratejik bir pivot ger\u00e7ekle\u015ftirmi\u015ftir."},{"question":"SAVA hisselerinin fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 2,40 $-3,40 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rmesi bekleniyor, ancak biyoteknoloji yat\u0131r\u0131mlar\u0131nda y\u00fcksek belirsizlik bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayan biri SAVA hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss seviyeleri belirleyin ve klinik geli\u015fmeleri yak\u0131ndan takip edin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Cassava Sciences (SAVA) hisseleri nereden al\u0131nabilir?","answer":"SAVA hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"SAVA hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Y\u00fcksek volatilite, klinik deneme sonu\u00e7lar\u0131 ve \u015firketin nakit pozisyonu gibi fakt\u00f6rler yat\u0131r\u0131m kararlar\u0131n\u0131zda \u00f6nemli rol oynar. Riskleri anlamak ve k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamak \u00f6nemlidir."},{"question":"Cassava Sciences'in stratejik de\u011fi\u015fikli\u011fi nedir?","answer":"\u015eirket, Alzheimer hastal\u0131\u011f\u0131 ara\u015ft\u0131rmalar\u0131ndan vazge\u00e7ip TSC ile ili\u015fkili epilepsi tedavilerine odaklanmak \u00fczere stratejik bir pivot ger\u00e7ekle\u015ftirmi\u015ftir."},{"question":"SAVA hisselerinin fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 2,40 $-3,40 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rmesi bekleniyor, ancak biyoteknoloji yat\u0131r\u0131mlar\u0131nda y\u00fcksek belirsizlik bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayan biri SAVA hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, stop-loss seviyeleri belirleyin ve klinik geli\u015fmeleri yak\u0131ndan takip edin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T11:56:21+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-19T11:56:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/\",\"name\":\"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-19T11:56:21+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/","og_locale":"tr_TR","og_type":"article","og_title":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T11:56:21+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-19T11:56:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/","name":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-19T11:56:21+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-cassava-sciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Cassava Sciences, Inc. (SAVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Cassava Sciences, Inc. (SAVA) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":337455,"slug":"how-to-buy-cassava-sciences","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Cassava Sciences, Inc. (SAVA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Cassava Sciences, Inc. (SAVA)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-cassava-sciences\/"},"pt_AA":{"locale":"pt_AA","id":337456,"slug":"how-to-buy-cassava-sciences","post_title":"Como comprar a\u00e7\u00f5es da Cassava Sciences, Inc. (SAVA) - Investimento em a\u00e7\u00f5es da Cassava Sciences, Inc. (SAVA)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-cassava-sciences\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/337454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=337454"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/337454\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=337454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=337454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=337454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}